ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report)'s stock price gapped up prior to trading on Monday . The stock had previously closed at $13.64, but opened at $14.43. ABIVAX Société Anonyme shares last traded at $14.28, with a volume of 8,408 shares trading hands.
Wall Street Analysts Forecast Growth
A number of analysts have issued reports on ABVX shares. BTIG Research started coverage on ABIVAX Société Anonyme in a report on Monday. They set a "buy" rating and a $43.00 price target for the company. Guggenheim began coverage on ABIVAX Société Anonyme in a report on Monday, April 29th. They issued a "buy" rating and a $50.00 target price for the company. Morgan Stanley boosted their target price on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the company an "equal weight" rating in a report on Thursday, April 11th. Finally, Piper Sandler initiated coverage on ABIVAX Société Anonyme in a report on Monday, April 29th. They issued an "overweight" rating and a $42.00 target price for the company. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $34.20.
Check Out Our Latest Report on ABIVAX Société Anonyme
ABIVAX Société Anonyme Stock Performance
The company has a 50-day simple moving average of $14.64 and a 200-day simple moving average of $12.66.
Institutional Investors Weigh In On ABIVAX Société Anonyme
Institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC boosted its stake in shares of ABIVAX Société Anonyme by 18.2% during the 1st quarter. Janus Henderson Group PLC now owns 851,839 shares of the company's stock worth $12,113,000 after acquiring an additional 131,414 shares in the last quarter. Kennedy Capital Management LLC lifted its stake in ABIVAX Société Anonyme by 35.3% in the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company's stock valued at $1,718,000 after buying an additional 31,331 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in ABIVAX Société Anonyme in the 1st quarter valued at approximately $81,000. Capstone Investment Advisors LLC lifted its stake in ABIVAX Société Anonyme by 9.0% in the 1st quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company's stock valued at $900,000 after buying an additional 5,199 shares in the last quarter. Finally, Blackstone Inc. purchased a new stake in ABIVAX Société Anonyme in the 4th quarter valued at approximately $25,345,000. Hedge funds and other institutional investors own 47.91% of the company's stock.
About ABIVAX Société Anonyme
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
Read More
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
